Ser1248
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1248  -  RAPGEF2 (human)

Site Information
AADsGRGsWTSCSsG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 30995200

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
breast cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CK1A (human) ( 1 )
Kinases, in vitro:
CK1A (human) ( 1 )
Treatments:
cycloheximide ( 1 ) , D4476 ( 1 ) , EGF ( 1 ) , HGF ( 1 ) , IC261 ( 1 ) , MG132 ( 1 ) , PDGF ( 1 ) , phorbol_ester ( 1 ) , SC-514 ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on RAPGEF2:
enzymatic activity, inhibited ( 1 ) , molecular association, regulation ( 1 ) , protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell motility, induced ( 1 )
Induce interaction with:
BTRC (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 1 )

References 

1

Magliozzi R, et al. (2013) Control of Epithelial Cell Migration and Invasion by the IKKβ- and CK1α-Mediated Degradation of RAPGEF2. Dev Cell 27, 574-85
24290981   Curated Info